Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,279.14 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts ↗

October 26, 2026

MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.

Via MarketBeat

Topics Artificial Intelligence

Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? ↗

October 26, 2026

IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: Fidelity’s FHLC or State Street’s XLV? ↗

October 26, 2026

XLV concentrates on 61 large-cap S&P 500 names, while FHLC casts a wider net with 365 holdings across mid and small caps. Both charge 0.08% annually.

Via The Motley Fool

Topics ETFs Stocks

Eli Lilly & Co (NYSE:LLY) Offers Dividend Quality for Growth-Focused Income Investors ↗

October 19, 2026

Via Chartmill

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings? ↗

October 25, 2026

Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector.

Via The Motley Fool

Topics Intellectual Property

The Nasdaq Just Had Its Worst Day in 4 Months. Here's the Level That Would Signal a Correction, and What History Says Investors Can Do About It. ↗

October 24, 2026

Tech stocks are selling off as investors question the payoff of artificial intelligence (AI) infrastructure spending.

Via The Motley Fool

Topics Artificial Intelligence Stocks

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks) ↗

October 23, 2026

These drugmakers are capitalizing on their pipeline successes.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly's Fast Growth Hasn't Slowed Its Progress As Sustainability Leader ↗

October 23, 2026

Eli Lilly's commitment to philanthropy, coupled with a dedication to environmental progress, make it a sustainability leader.

Via Investor's Business Daily

Topics Artificial Intelligence

3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach ↗

October 23, 2026

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.

Via MarketBeat

The S&P 500 May Depend on the Fortunes of These 3 Companies Right Now. Here’s the Good News and the Bad News for Investors. ↗

October 23, 2026

These companies make up about 20% of the index.

Via The Motley Fool

Topics Economy Stocks

Q2 earnings highs and lows: Eli Lilly (NYSE:LLY) vs the rest of the branded pharmaceuticals stocks

October 22, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026? ↗

October 22, 2026

Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.

Via The Motley Fool

Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results? ↗

October 22, 2026

Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.

Via The Motley Fool

Topics Artificial Intelligence Lawsuit

Vanguard Health Care ETF vs iShares U.S. Healthcare ETF ↗

October 21, 2026

VHT's 411 holdings and 0.09% expense ratio deliver identical 5-year returns to IYH's concentrated 100-stock portfolio, raising questions about whether lower costs justify broader diversification.

Via The Motley Fool

Topics ETFs

Where Will Novo Stock Be in 10 Years? ↗

October 21, 2026

The company may lean on its core therapeutic area to help it overcome recent headwinds.

Via The Motley Fool

Topics Intellectual Property

Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs ↗

October 21, 2026

Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers.

Via MarketBeat

Topics Artificial Intelligence ETFs

Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 ↗

October 21, 2026

The market has rewarded this biotech for its breakthroughs.

Via The Motley Fool

Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? ↗

October 21, 2026

Its leading investigational drug demonstrated relatively high levels of weight loss in a late-stage clinical trial.

Via The Motley Fool

Here's What I'm Planning With My Eli Lilly Position ↗

October 20, 2026

The pharmaceutical industry is relatively less correlated to the rest of the economy, and that's a diversification benefit for investors.

Via The Motley Fool

Topics Economy

Stock Market Midday, Oct. 20: Blue Chips Rally, Eli Lilly Gains 5% ↗

October 20, 2026

On Oct. 20, 2026, major U.S. indexes gained as falling oil prices boosted blue chips and semiconductors edged upwards.

Via The Motley Fool

Topics Artificial Intelligence Earnings Stocks

S&P 500 Top Movers: Gainers and Losers From Today's US Session ↗

October 20, 2026

Via Chartmill

Topics Stocks

October 20, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

Topics Energy

Is Eli Lilly Stock a Buy Right Now? ↗

October 19, 2026

Eli Lilly is growing quickly, lowering realized prices, and building its next wave of drugs. Here's what the numbers say about margins, valuation, and the catalysts that matter next.

Via The Motley Fool

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market ↗

October 19, 2026

Is this company the biggest dark horse in the chronic weight management space?

Via The Motley Fool

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning ↗

October 19, 2026

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

Via MarketBeat

Topics Artificial Intelligence

What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs ↗

October 19, 2026

Polls suggest a divided government after the midterms, a scenario that historically benefits healthcare stocks. Here's how the XLV and IHF ETFs compare for investors eyeing the sector.

Via MarketBeat

Topics ETFs

Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It ↗

October 19, 2026

Buffett has warned about "gambling" in the market.

Via The Motley Fool

Topics Intellectual Property Retirement

Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. ↗

October 18, 2026

Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.

Via The Motley Fool

Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade? ↗

October 18, 2026

Novo is facing some headwinds, but it has a plan to overcome them.

Via The Motley Fool

Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. ↗

October 18, 2026

It was Griffin's biggest add for Citadel last quarter.

Via The Motley Fool

Topics Economy

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.